Novartis Sees Clear Opportunity in Encore Vision’s Unique Approach to Correcting Presbyopia
Frederic Guerard, head of Novartis’ ophthalmology franchise, explains why the global giant was the last strategic standing in the competitive bidding to acquire the promising, but very early stage, start-up. Novartis will resume testing of the new presbyopia-correcting ophthalmic solution, now dubbed UNR-844.
Podcast Guest:
Frederic Guerard
Frederic Guerard is the Worldwide Business Franchise Head, Ophthalmology for Novartis after having served as Global Business Franchise Head Pharmaceuticals for Alcon.